Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
Introduction Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce. Objective To study the effect of 16‐week treatment with dupilumab on clinical response and serum biomarkers in adult pati...
Gespeichert in:
| Veröffentlicht in: | Allergy (Copenhagen) 2020-01, Vol.75 (1), p.116-126 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 126 |
|---|---|
| container_issue | 1 |
| container_start_page | 116 |
| container_title | Allergy (Copenhagen) |
| container_volume | 75 |
| creator | Ariëns, Lieneke F. M. Schaft, Jorien Bakker, Daphne S. Balak, Deepak Romeijn, Margreet L. E. Kouwenhoven, Tessa Kamsteeg, Marijke Giovannone, Barbara Drylewicz, Julia Amerongen, Cynthia Catalina Aurora Delemarre, Evelien M. Knol, Edward F. Wijk, Femke Nierkens, Stefan Thijs, Judith L. Schuttelaar, Marie L. A. Bruin‐Weller, Marjolein S. |
| description | Introduction
Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce.
Objective
To study the effect of 16‐week treatment with dupilumab on clinical response and serum biomarkers in adult patients with moderate‐severe AD in daily practice.
Methods
Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen‐week clinical effectiveness of dupilumab was expressed as number of patients achieving EASI‐50 (Eczema Area and Severity Index) or EASI‐75, as well as patient‐reported outcomes measures (Patient‐Oriented Eczema Measure, Dermatology Life Quality Index, Numeric Rating Scale pruritus). Twenty‐one biomarkers were measured in patients treated with dupilumab without concomitant use of oral immunosuppressive drugs at five different time points (baseline, 4, 8, 12, and 16 weeks).
Results
In total, 138 patients treated with dupilumab in daily practice were included. This cohort consisted of patients with very difficult‐to‐treat AD, including 84 (61%) patients who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI‐50 and EASI‐75 were achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. The most reported side effect was conjunctivitis, occurring in 47 (34%) patients. During dupilumab treatment, disease severity‐related serum biomarkers (TARC, PARC, periostin, and IL‐22), eotaxin‐1, and eotaxin‐3 significantly decreased.
Conclusion
Treatment with dupilumab significantly improved disease severity and decreased severity‐related serum biomarkers in patients with very difficult‐to‐treat AD in a daily practice setting.
This study evaluated the clinical effectiveness and safety of 16‐weeks of dupilumab treatment in adults with AD. Dupilumab treatment significantly suppressed disease severity‐related serum biomarkers and eosinophil chemokines. By the end of the treatment, the EASI‐50 and EASI‐75 was achieved by 86% and 62% of patients, respectively.
Abbreviations: AD: Atopic dermatitis; DLQI: Dermatology life quality index; EASI: Eczema area and severity index; IGA: Investigators global assessment; NRS: Numeric rating scale; PARC: Pulmonary and activation‐regulated chemokine; POEM: Patient‐oriented eczema measure; TARC: Thymus‐ and activation‐regulated chemokine |
| doi_str_mv | 10.1111/all.14080 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2334568284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2334568284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4540-db471133bf8a19835b7adbf21a668097c58e5f6f6fb5421dd1a1a57a5905d2673</originalsourceid><addsrcrecordid>eNp1kU9u1TAQhy0Eoo_CggugkVixSGvHcRKzKy0FpCexgXU08Z_WxYmD7RRlxxG4BffiJLi8wg5b8kijz9_I_hHynNETVtYpen_CGtrTB2THuOwrKaV4SHaUUVE1gvdH5ElKN5TSrpb0MTniTEjOG74jPy_Wxfl1whFcglsTNzDWGpXdrQE3A4LHeGVAhesQMwQL2lnr1Orzr-8_crg7osEMqEsLMIfFKdAmTphdLsqlVDPn9BouXUwZlHezU-gBZw2jCxPGLyZCNKncT2BjmCBfG3jjwgVupX_lUo7bU_LIok_m2X09Jp8v3346f1_tP777cH62r1QjGlrpsekY43y0PTLZczF2qEdbM2zbnspOid4I25Y9iqZmWjNkKDoUkgpdtx0_Ji8P3iWGr6tJebgJa5zLyKEuPybavu6bQr06UCqGlKKxwxJdeck2MDrcRTKUSIY_kRT2xb1xHSej_5F_MyjA6QH45rzZ_m8azvb7g_I3-kyaOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2334568284</pqid></control><display><type>article</type><title>Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry</title><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ariëns, Lieneke F. M. ; Schaft, Jorien ; Bakker, Daphne S. ; Balak, Deepak ; Romeijn, Margreet L. E. ; Kouwenhoven, Tessa ; Kamsteeg, Marijke ; Giovannone, Barbara ; Drylewicz, Julia ; Amerongen, Cynthia Catalina Aurora ; Delemarre, Evelien M. ; Knol, Edward F. ; Wijk, Femke ; Nierkens, Stefan ; Thijs, Judith L. ; Schuttelaar, Marie L. A. ; Bruin‐Weller, Marjolein S.</creator><creatorcontrib>Ariëns, Lieneke F. M. ; Schaft, Jorien ; Bakker, Daphne S. ; Balak, Deepak ; Romeijn, Margreet L. E. ; Kouwenhoven, Tessa ; Kamsteeg, Marijke ; Giovannone, Barbara ; Drylewicz, Julia ; Amerongen, Cynthia Catalina Aurora ; Delemarre, Evelien M. ; Knol, Edward F. ; Wijk, Femke ; Nierkens, Stefan ; Thijs, Judith L. ; Schuttelaar, Marie L. A. ; Bruin‐Weller, Marjolein S.</creatorcontrib><description>Introduction
Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce.
Objective
To study the effect of 16‐week treatment with dupilumab on clinical response and serum biomarkers in adult patients with moderate‐severe AD in daily practice.
Methods
Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen‐week clinical effectiveness of dupilumab was expressed as number of patients achieving EASI‐50 (Eczema Area and Severity Index) or EASI‐75, as well as patient‐reported outcomes measures (Patient‐Oriented Eczema Measure, Dermatology Life Quality Index, Numeric Rating Scale pruritus). Twenty‐one biomarkers were measured in patients treated with dupilumab without concomitant use of oral immunosuppressive drugs at five different time points (baseline, 4, 8, 12, and 16 weeks).
Results
In total, 138 patients treated with dupilumab in daily practice were included. This cohort consisted of patients with very difficult‐to‐treat AD, including 84 (61%) patients who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI‐50 and EASI‐75 were achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. The most reported side effect was conjunctivitis, occurring in 47 (34%) patients. During dupilumab treatment, disease severity‐related serum biomarkers (TARC, PARC, periostin, and IL‐22), eotaxin‐1, and eotaxin‐3 significantly decreased.
Conclusion
Treatment with dupilumab significantly improved disease severity and decreased severity‐related serum biomarkers in patients with very difficult‐to‐treat AD in a daily practice setting.
This study evaluated the clinical effectiveness and safety of 16‐weeks of dupilumab treatment in adults with AD. Dupilumab treatment significantly suppressed disease severity‐related serum biomarkers and eosinophil chemokines. By the end of the treatment, the EASI‐50 and EASI‐75 was achieved by 86% and 62% of patients, respectively.
Abbreviations: AD: Atopic dermatitis; DLQI: Dermatology life quality index; EASI: Eczema area and severity index; IGA: Investigators global assessment; NRS: Numeric rating scale; PARC: Pulmonary and activation‐regulated chemokine; POEM: Patient‐oriented eczema measure; TARC: Thymus‐ and activation‐regulated chemokine</description><identifier>ISSN: 0105-4538</identifier><identifier>EISSN: 1398-9995</identifier><identifier>DOI: 10.1111/all.14080</identifier><identifier>PMID: 31593343</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing Ltd</publisher><subject>Adult ; Anti-Allergic Agents - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Atopic dermatitis ; Biomarkers ; Biomarkers - blood ; Cohort Studies ; Conjunctivitis ; daily practice ; Dermatitis ; Dermatitis, Atopic - drug therapy ; Dermatology ; disease severity ; dupilumab ; Eczema ; Eotaxin ; Female ; Humans ; Immunosuppressive agents ; Immunotherapy ; Male ; Medical treatment ; Middle Aged ; Monoclonal antibodies ; Patients ; Pruritus ; Quality of life ; Registries ; Side effects ; Skin diseases ; Treatment Outcome</subject><ispartof>Allergy (Copenhagen), 2020-01, Vol.75 (1), p.116-126</ispartof><rights>2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.</rights><rights>Copyright © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4540-db471133bf8a19835b7adbf21a668097c58e5f6f6fb5421dd1a1a57a5905d2673</citedby><cites>FETCH-LOGICAL-c4540-db471133bf8a19835b7adbf21a668097c58e5f6f6fb5421dd1a1a57a5905d2673</cites><orcidid>0000-0001-5256-0091 ; 0000-0003-2753-5235 ; 0000-0002-1249-6993 ; 0000-0002-9434-8459</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fall.14080$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fall.14080$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31593343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ariëns, Lieneke F. M.</creatorcontrib><creatorcontrib>Schaft, Jorien</creatorcontrib><creatorcontrib>Bakker, Daphne S.</creatorcontrib><creatorcontrib>Balak, Deepak</creatorcontrib><creatorcontrib>Romeijn, Margreet L. E.</creatorcontrib><creatorcontrib>Kouwenhoven, Tessa</creatorcontrib><creatorcontrib>Kamsteeg, Marijke</creatorcontrib><creatorcontrib>Giovannone, Barbara</creatorcontrib><creatorcontrib>Drylewicz, Julia</creatorcontrib><creatorcontrib>Amerongen, Cynthia Catalina Aurora</creatorcontrib><creatorcontrib>Delemarre, Evelien M.</creatorcontrib><creatorcontrib>Knol, Edward F.</creatorcontrib><creatorcontrib>Wijk, Femke</creatorcontrib><creatorcontrib>Nierkens, Stefan</creatorcontrib><creatorcontrib>Thijs, Judith L.</creatorcontrib><creatorcontrib>Schuttelaar, Marie L. A.</creatorcontrib><creatorcontrib>Bruin‐Weller, Marjolein S.</creatorcontrib><title>Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry</title><title>Allergy (Copenhagen)</title><addtitle>Allergy</addtitle><description>Introduction
Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce.
Objective
To study the effect of 16‐week treatment with dupilumab on clinical response and serum biomarkers in adult patients with moderate‐severe AD in daily practice.
Methods
Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen‐week clinical effectiveness of dupilumab was expressed as number of patients achieving EASI‐50 (Eczema Area and Severity Index) or EASI‐75, as well as patient‐reported outcomes measures (Patient‐Oriented Eczema Measure, Dermatology Life Quality Index, Numeric Rating Scale pruritus). Twenty‐one biomarkers were measured in patients treated with dupilumab without concomitant use of oral immunosuppressive drugs at five different time points (baseline, 4, 8, 12, and 16 weeks).
Results
In total, 138 patients treated with dupilumab in daily practice were included. This cohort consisted of patients with very difficult‐to‐treat AD, including 84 (61%) patients who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI‐50 and EASI‐75 were achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. The most reported side effect was conjunctivitis, occurring in 47 (34%) patients. During dupilumab treatment, disease severity‐related serum biomarkers (TARC, PARC, periostin, and IL‐22), eotaxin‐1, and eotaxin‐3 significantly decreased.
Conclusion
Treatment with dupilumab significantly improved disease severity and decreased severity‐related serum biomarkers in patients with very difficult‐to‐treat AD in a daily practice setting.
This study evaluated the clinical effectiveness and safety of 16‐weeks of dupilumab treatment in adults with AD. Dupilumab treatment significantly suppressed disease severity‐related serum biomarkers and eosinophil chemokines. By the end of the treatment, the EASI‐50 and EASI‐75 was achieved by 86% and 62% of patients, respectively.
Abbreviations: AD: Atopic dermatitis; DLQI: Dermatology life quality index; EASI: Eczema area and severity index; IGA: Investigators global assessment; NRS: Numeric rating scale; PARC: Pulmonary and activation‐regulated chemokine; POEM: Patient‐oriented eczema measure; TARC: Thymus‐ and activation‐regulated chemokine</description><subject>Adult</subject><subject>Anti-Allergic Agents - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Atopic dermatitis</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Cohort Studies</subject><subject>Conjunctivitis</subject><subject>daily practice</subject><subject>Dermatitis</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatology</subject><subject>disease severity</subject><subject>dupilumab</subject><subject>Eczema</subject><subject>Eotaxin</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Immunotherapy</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Pruritus</subject><subject>Quality of life</subject><subject>Registries</subject><subject>Side effects</subject><subject>Skin diseases</subject><subject>Treatment Outcome</subject><issn>0105-4538</issn><issn>1398-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9u1TAQhy0Eoo_CggugkVixSGvHcRKzKy0FpCexgXU08Z_WxYmD7RRlxxG4BffiJLi8wg5b8kijz9_I_hHynNETVtYpen_CGtrTB2THuOwrKaV4SHaUUVE1gvdH5ElKN5TSrpb0MTniTEjOG74jPy_Wxfl1whFcglsTNzDWGpXdrQE3A4LHeGVAhesQMwQL2lnr1Orzr-8_crg7osEMqEsLMIfFKdAmTphdLsqlVDPn9BouXUwZlHezU-gBZw2jCxPGLyZCNKncT2BjmCBfG3jjwgVupX_lUo7bU_LIok_m2X09Jp8v3346f1_tP777cH62r1QjGlrpsekY43y0PTLZczF2qEdbM2zbnspOid4I25Y9iqZmWjNkKDoUkgpdtx0_Ji8P3iWGr6tJebgJa5zLyKEuPybavu6bQr06UCqGlKKxwxJdeck2MDrcRTKUSIY_kRT2xb1xHSej_5F_MyjA6QH45rzZ_m8azvb7g_I3-kyaOQ</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Ariëns, Lieneke F. M.</creator><creator>Schaft, Jorien</creator><creator>Bakker, Daphne S.</creator><creator>Balak, Deepak</creator><creator>Romeijn, Margreet L. E.</creator><creator>Kouwenhoven, Tessa</creator><creator>Kamsteeg, Marijke</creator><creator>Giovannone, Barbara</creator><creator>Drylewicz, Julia</creator><creator>Amerongen, Cynthia Catalina Aurora</creator><creator>Delemarre, Evelien M.</creator><creator>Knol, Edward F.</creator><creator>Wijk, Femke</creator><creator>Nierkens, Stefan</creator><creator>Thijs, Judith L.</creator><creator>Schuttelaar, Marie L. A.</creator><creator>Bruin‐Weller, Marjolein S.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0001-5256-0091</orcidid><orcidid>https://orcid.org/0000-0003-2753-5235</orcidid><orcidid>https://orcid.org/0000-0002-1249-6993</orcidid><orcidid>https://orcid.org/0000-0002-9434-8459</orcidid></search><sort><creationdate>202001</creationdate><title>Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry</title><author>Ariëns, Lieneke F. M. ; Schaft, Jorien ; Bakker, Daphne S. ; Balak, Deepak ; Romeijn, Margreet L. E. ; Kouwenhoven, Tessa ; Kamsteeg, Marijke ; Giovannone, Barbara ; Drylewicz, Julia ; Amerongen, Cynthia Catalina Aurora ; Delemarre, Evelien M. ; Knol, Edward F. ; Wijk, Femke ; Nierkens, Stefan ; Thijs, Judith L. ; Schuttelaar, Marie L. A. ; Bruin‐Weller, Marjolein S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4540-db471133bf8a19835b7adbf21a668097c58e5f6f6fb5421dd1a1a57a5905d2673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Anti-Allergic Agents - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Atopic dermatitis</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Cohort Studies</topic><topic>Conjunctivitis</topic><topic>daily practice</topic><topic>Dermatitis</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatology</topic><topic>disease severity</topic><topic>dupilumab</topic><topic>Eczema</topic><topic>Eotaxin</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Immunotherapy</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Pruritus</topic><topic>Quality of life</topic><topic>Registries</topic><topic>Side effects</topic><topic>Skin diseases</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ariëns, Lieneke F. M.</creatorcontrib><creatorcontrib>Schaft, Jorien</creatorcontrib><creatorcontrib>Bakker, Daphne S.</creatorcontrib><creatorcontrib>Balak, Deepak</creatorcontrib><creatorcontrib>Romeijn, Margreet L. E.</creatorcontrib><creatorcontrib>Kouwenhoven, Tessa</creatorcontrib><creatorcontrib>Kamsteeg, Marijke</creatorcontrib><creatorcontrib>Giovannone, Barbara</creatorcontrib><creatorcontrib>Drylewicz, Julia</creatorcontrib><creatorcontrib>Amerongen, Cynthia Catalina Aurora</creatorcontrib><creatorcontrib>Delemarre, Evelien M.</creatorcontrib><creatorcontrib>Knol, Edward F.</creatorcontrib><creatorcontrib>Wijk, Femke</creatorcontrib><creatorcontrib>Nierkens, Stefan</creatorcontrib><creatorcontrib>Thijs, Judith L.</creatorcontrib><creatorcontrib>Schuttelaar, Marie L. A.</creatorcontrib><creatorcontrib>Bruin‐Weller, Marjolein S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Allergy (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ariëns, Lieneke F. M.</au><au>Schaft, Jorien</au><au>Bakker, Daphne S.</au><au>Balak, Deepak</au><au>Romeijn, Margreet L. E.</au><au>Kouwenhoven, Tessa</au><au>Kamsteeg, Marijke</au><au>Giovannone, Barbara</au><au>Drylewicz, Julia</au><au>Amerongen, Cynthia Catalina Aurora</au><au>Delemarre, Evelien M.</au><au>Knol, Edward F.</au><au>Wijk, Femke</au><au>Nierkens, Stefan</au><au>Thijs, Judith L.</au><au>Schuttelaar, Marie L. A.</au><au>Bruin‐Weller, Marjolein S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry</atitle><jtitle>Allergy (Copenhagen)</jtitle><addtitle>Allergy</addtitle><date>2020-01</date><risdate>2020</risdate><volume>75</volume><issue>1</issue><spage>116</spage><epage>126</epage><pages>116-126</pages><issn>0105-4538</issn><eissn>1398-9995</eissn><abstract>Introduction
Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce.
Objective
To study the effect of 16‐week treatment with dupilumab on clinical response and serum biomarkers in adult patients with moderate‐severe AD in daily practice.
Methods
Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen‐week clinical effectiveness of dupilumab was expressed as number of patients achieving EASI‐50 (Eczema Area and Severity Index) or EASI‐75, as well as patient‐reported outcomes measures (Patient‐Oriented Eczema Measure, Dermatology Life Quality Index, Numeric Rating Scale pruritus). Twenty‐one biomarkers were measured in patients treated with dupilumab without concomitant use of oral immunosuppressive drugs at five different time points (baseline, 4, 8, 12, and 16 weeks).
Results
In total, 138 patients treated with dupilumab in daily practice were included. This cohort consisted of patients with very difficult‐to‐treat AD, including 84 (61%) patients who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI‐50 and EASI‐75 were achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. The most reported side effect was conjunctivitis, occurring in 47 (34%) patients. During dupilumab treatment, disease severity‐related serum biomarkers (TARC, PARC, periostin, and IL‐22), eotaxin‐1, and eotaxin‐3 significantly decreased.
Conclusion
Treatment with dupilumab significantly improved disease severity and decreased severity‐related serum biomarkers in patients with very difficult‐to‐treat AD in a daily practice setting.
This study evaluated the clinical effectiveness and safety of 16‐weeks of dupilumab treatment in adults with AD. Dupilumab treatment significantly suppressed disease severity‐related serum biomarkers and eosinophil chemokines. By the end of the treatment, the EASI‐50 and EASI‐75 was achieved by 86% and 62% of patients, respectively.
Abbreviations: AD: Atopic dermatitis; DLQI: Dermatology life quality index; EASI: Eczema area and severity index; IGA: Investigators global assessment; NRS: Numeric rating scale; PARC: Pulmonary and activation‐regulated chemokine; POEM: Patient‐oriented eczema measure; TARC: Thymus‐ and activation‐regulated chemokine</abstract><cop>Denmark</cop><pub>Blackwell Publishing Ltd</pub><pmid>31593343</pmid><doi>10.1111/all.14080</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5256-0091</orcidid><orcidid>https://orcid.org/0000-0003-2753-5235</orcidid><orcidid>https://orcid.org/0000-0002-1249-6993</orcidid><orcidid>https://orcid.org/0000-0002-9434-8459</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0105-4538 |
| ispartof | Allergy (Copenhagen), 2020-01, Vol.75 (1), p.116-126 |
| issn | 0105-4538 1398-9995 |
| language | eng |
| recordid | cdi_proquest_journals_2334568284 |
| source | MEDLINE; Wiley Online Library Free Content; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Anti-Allergic Agents - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Atopic dermatitis Biomarkers Biomarkers - blood Cohort Studies Conjunctivitis daily practice Dermatitis Dermatitis, Atopic - drug therapy Dermatology disease severity dupilumab Eczema Eotaxin Female Humans Immunosuppressive agents Immunotherapy Male Medical treatment Middle Aged Monoclonal antibodies Patients Pruritus Quality of life Registries Side effects Skin diseases Treatment Outcome |
| title | Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A24%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dupilumab%20is%20very%20effective%20in%20a%20large%20cohort%20of%20difficult%E2%80%90to%E2%80%90treat%20adult%20atopic%20dermatitis%20patients:%20First%20clinical%20and%20biomarker%20results%20from%20the%20BioDay%20registry&rft.jtitle=Allergy%20(Copenhagen)&rft.au=Ari%C3%ABns,%20Lieneke%20F.%20M.&rft.date=2020-01&rft.volume=75&rft.issue=1&rft.spage=116&rft.epage=126&rft.pages=116-126&rft.issn=0105-4538&rft.eissn=1398-9995&rft_id=info:doi/10.1111/all.14080&rft_dat=%3Cproquest_cross%3E2334568284%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2334568284&rft_id=info:pmid/31593343&rfr_iscdi=true |